Quick Comparison

EGF (Epidermal Growth Factor)Tretinoin
Typical ConcentrationConcentrations vary by product (typically measured in ppm or sh-oligopeptide-1 percentage). Applied once or twice daily. Best used after procedures or on aging skin. Apply before oils/occlusives. Store in refrigerator for stability.Concentrations: 0.025%, 0.05%, 0.1%. Start with 0.025% every other night for 4-6 weeks, then increase frequency. Apply pea-sized amount to dry face 20 minutes after cleansing. Always use with SPF 30+ during the day. Retinization period: 4-12 weeks of initial irritation.
ApplicationTopical (serum, cream, ampoule). Apply to clean skin. Temperature-sensitive — some products require refrigeration.Topical (cream, gel, microsphere). Apply to clean, dry skin at night. Microsphere formulations (Retin-A Micro) release tretinoin slowly, reducing irritation.
Research Papers10 papers10 papers
Categories

Mechanism of Action

EGF (Epidermal Growth Factor)

EGF binds EGFR/ErbB1 on keratinocytes and fibroblasts, triggering dimerization and autophosphorylation. Activates MAPK/ERK (Ras-Raf-MEK-ERK) and PI3K/AKT pathways, promoting proliferation, migration (actin reorganization, focal adhesion turnover), and differentiation. Upregulates cyclin D1, inhibits p27. Stimulates fibroblast collagen types I/III and hyaluronic acid via HAS2. In wound healing, accelerates re-epithelialization via keratinocyte migration and reduces scarring via TGF-beta modulation. For anti-aging, promotes cellular renewal and extracellular matrix production. Theoretical cancer concern from EGFR's growth role — topical EGF has not been shown to penetrate to basal layer or systemic circulation significantly.

Tretinoin

Tretinoin binds nuclear retinoic acid receptors (RAR-alpha, beta, gamma), forming RAR/RXR heterodimers that bind retinoic acid response elements and activate gene transcription. This accelerates keratinocyte proliferation, reducing stratum corneum transit from ~28 to ~14 days. In the dermis, tretinoin stimulates fibroblasts and upregulates collagen I and III via TGF-beta while downregulating MMP-1, MMP-3, and MMP-9 that degrade the extracellular matrix. It normalizes melanocyte distribution and melanosome transfer. In acne, it prevents microcomedo formation by normalizing follicular keratinocyte differentiation and reducing corneocyte cohesion. RAR activation also modulates genes for epidermal growth factors and differentiation markers.

Risks & Safety

EGF (Epidermal Growth Factor)

Common

Very well-tolerated.

Serious

Theoretical concern about promoting growth of pre-existing skin cancers (unproven but debated).

Rare

Mild irritation.

Tretinoin

Common

Dryness, peeling, redness, increased sun sensitivity (mandatory SPF). Initial purging (breakouts) for 4-8 weeks.

Serious

Teratogenic — absolutely contraindicated in pregnancy and breastfeeding.

Rare

Severe irritant contact dermatitis, eczema flare-ups.

Full Profiles